NCT06015126View on ClinicalTrials.gov

Efficacy and Safety of Metronomic Oral Vinorelbine Plus Anlotinib in HER2-negative Metastatic Breast Cancer Patients

NARecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 5, 2022

Primary Completion Date

January 31, 2025

Study Completion Date

January 31, 2026

Conditions
Breast Cancer
Interventions
DRUG

metronomic oral vinorelbine plus anlotinib

To clarify the efficacy and safety of metronomic oral vinorelbine plus anlotinib in HER2-negative metastatic breast cancer patients, adding new data for the posterior treatment of HER2-negative advanced breast cancer

Trial Locations (1)

710100

RECRUITING

Xi'an International Medical Center Hospital, Xi'an

All Listed Sponsors
lead

Yan Xue

OTHER